title: Tocilizumab, MS, and NMOSD.
authors.affiliation: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany ingo.kleiter@rub.de.
authors.forename: Ingo
authors.initials: I
authors.lastname: Kleiter
authors.affiliation: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
authors.forename: Ilya
authors.initials: I
authors.lastname: Ayzenberg
authors.affiliation: Multiple Sclerosis Center, National Center of Neurology and Psychiatry, and Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Araki
authors.affiliation: Multiple Sclerosis Center, National Center of Neurology and Psychiatry, and Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamura
authors.affiliation: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009471:Neuromyelitis Optica
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab